MAPT and supranuclear palsy, progressive, 1: This, however, does not represent the conditions that we observed in human PSP patients, in human cells with annonacin treatment or 4R tau overexpression, or in P301S tau transgenic mice at earlier stages of pathology, which were characterized by low levels of EIF2A or pEIF2A.